+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Neuralgia Treatment Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 197 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 5146088
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neuralgia treatment market is undergoing rapid transformation, offering senior decision-makers timely intelligence on evolving therapeutic strategies, critical innovations, and shifting global supply parameters. This report presents a comprehensive analysis of current and emerging modalities, regulatory shifts, and patient preference trends—essential insight for organizations navigating this complex healthcare landscape.

Market Snapshot: Neuralgia Treatment Market Growth and Dynamics

The Neuralgia Treatment Market grew from USD 1.20 billion in 2024 to USD 1.35 billion in 2025. It is expected to continue growing at a CAGR of 12.77%, reaching USD 3.14 billion by 2032. Market expansion is driven by demographic changes, increasing prevalence of neuropathic conditions, and advancements in both pharmacological and non-pharmacological therapies. Innovations in neuromodulation, patient-centric clinical trial designs, and integration of digital health platforms are accelerating the global uptake of new solutions for neuralgia.

Scope & Segmentation

  • Treatment Types: Acupuncture, neuromodulation, physical therapy, pharmacological interventions.
  • Delivery Modes: Injectable, oral, topical, transdermal.
  • End Users: Ambulatory surgical centers, home healthcare, hospitals, specialty clinics.
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy.
  • Indications: Chemotherapy-induced neuralgia, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia.
  • Drug Classes: Anticonvulsants, antidepressants, local anesthetics, NSAIDs, opioids, topical agents.
  • Geographic Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe (including United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
  • Leading Companies: Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., Johnson & Johnson, GlaxoSmithKline plc, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Grünenthal GmbH, Viatris Inc.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Emerging therapies are integrating advanced neuromodulation technologies with multimodal approaches, enabling tailored interventions for distinct patient groups.
  • Digital health innovations, such as telemedicine and wearables, are enhancing treatment monitoring and optimizing patient adherence.
  • Selective sodium channel blockers and biologics are reshaping pain management by minimizing off-target effects and advancing patient tolerance.
  • Industry collaborations between pharmaceutical, medtech, and biotech sectors are accelerating the development of next-generation combination therapies.
  • Patient-centric trial models, supported by real-world data, are influencing faster regulatory approvals and informing future care protocols.
  • Market segmentation—by treatment type, delivery mode, end user, and distribution channel—remains key for product development and targeted commercialization.

Tariff Impact: Navigating Geopolitical and Supply Chain Complexities

The 2025 U.S. tariff adjustments have increased manufacturing and import costs for medical devices and pharmaceutical components in neuralgia treatment. Sourcing specialized materials for neuromodulation implants and active pharmaceutical ingredients has become more challenging, leading many companies to revisit supplier agreements and explore regional production. Strategic responses have included localizing production, implementing tariff mitigation tactics, and engaging regulatory bodies to expedite customs processes. As a result, resilient supply chains and localized sourcing are critical for maintaining affordability and securing uninterrupted access to therapies.

Primary Keyword: Neuralgia Treatment Market

Methodology & Data Sources

This report leverages an integrated research approach, combining secondary reviews of peer-reviewed publications and regulatory data with primary interviews of key opinion leaders, clinicians, and industry executives. Quantitative analysis, stakeholder feedback, and real-world observations ensure robust evidence-based findings and actionable recommendations.

Why This Report Matters

  • Enables strategic decisions by highlighting disruptive innovations and actionable market segmentation.
  • Offers thorough analysis of regional market dynamics, competitive intelligence, and supply chain resilience.
  • Supports R&D prioritization and investment planning, underscored by expert insight and scenario analysis.

Conclusion

The evolving neuralgia treatment market requires agile strategies, robust partnerships, and innovative solutions. Accessing the comprehensive intelligence in this report equips organizations to drive growth, improve patient outcomes, and maintain supply resilience in a dynamic market environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Expanding use of gene therapy approaches for hereditary and idiopathic neuralgia treatment
5.2. Integration of neuromodulation devices with closed loop feedback systems for personalized pain relief
5.3. Emergence of targeted monoclonal antibody therapies for refractory neuropathic pain management
5.4. Adoption of AI driven predictive analytics platforms to optimize neuralgia treatment regimens
5.5. Advancements in minimally invasive percutaneous nerve ablation techniques for chronic neuralgia
5.6. Development of combination pharmacotherapy and neurostimulation protocols for enhanced analgesia
5.7. Growing pipeline of regenerative stem cell interventions for peripheral nerve repair in neuralgia patients
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Neuralgia Treatment Market, by Treatment Type
8.1. Non Pharmacological
8.1.1. Acupuncture
8.1.2. Neuromodulation
8.1.3. Physical Therapy
8.2. Pharmacological
9. Neuralgia Treatment Market, by Delivery Mode
9.1. Injectable
9.2. Oral
9.3. Topical
9.4. Transdermal
10. Neuralgia Treatment Market, by End User
10.1. Ambulatory Surgical Centers
10.2. Home Healthcare
10.3. Hospitals
10.4. Specialty Clinics
11. Neuralgia Treatment Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Neuralgia Treatment Market, by Indication
12.1. Chemotherapy Induced Neuralgia
12.2. Diabetic Neuropathy
12.3. Postherpetic Neuralgia
12.4. Trigeminal Neuralgia
13. Neuralgia Treatment Market, by Drug Class
13.1. Anticonvulsants
13.2. Antidepressants
13.3. Local Anesthetics
13.4. NSAIDs
13.5. Opioids
13.6. Topical Agents
14. Neuralgia Treatment Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Neuralgia Treatment Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Neuralgia Treatment Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Eli Lilly and Company
17.3.3. Novartis AG
17.3.4. Sanofi S.A.
17.3.5. Johnson & Johnson
17.3.6. GlaxoSmithKline plc
17.3.7. AbbVie Inc.
17.3.8. Teva Pharmaceutical Industries Ltd.
17.3.9. Grünenthal GmbH
17.3.10. Viatris Inc.
List of Tables
List of Figures

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this Neuralgia Treatment market report include:
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi S.A.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Grünenthal GmbH
  • Viatris Inc.

Table Information